{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T05:56:22Z","timestamp":1722664582618},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clinthera.2015.03.023","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T22:05:19Z","timestamp":1429999519000},"page":"1573-1586","source":"Crossref","is-referenced-by-count":5,"title":["Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Megan","family":"Murphy-Menezes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.03.023_bib1","series-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","year":"2014"},{"key":"10.1016\/j.clinthera.2015.03.023_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2151458510378105","article-title":"The 1-year mortality of patients treated in a hip fracture program for elders","volume":"1","author":"Schnell","year":"2010","journal-title":"Geriatr Orthop Surg Rehab"},{"key":"10.1016\/j.clinthera.2015.03.023_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2015.03.023_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16","author":"Watts","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clinthera.2015.03.023_bib5","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2015.03.023_bib6","unstructured":"Fosamax [package insert]. Whitehouse Station, NJ: Merck; 2014."},{"key":"10.1016\/j.clinthera.2015.03.023_bib7","unstructured":"Actonel [package insert]. Rockaway, NJ: Warner Chilcot; 2013."},{"key":"10.1016\/j.clinthera.2015.03.023_bib8","unstructured":"Boniva [package insert]. South San Francisco, CA: Genentech; 2013."},{"key":"10.1016\/j.clinthera.2015.03.023_bib9","unstructured":"Reclast [package insert]. East Hanover, NJ: Novartis; 2013."},{"key":"10.1016\/j.clinthera.2015.03.023_bib10","unstructured":"Prolia [package insert]. Thousand Oaks, CA: Amgen; 2014."},{"key":"10.1016\/j.clinthera.2015.03.023_bib11","doi-asserted-by":"crossref","unstructured":"Silverman S, Schousboe B, Gold D. Oral bisphosphonate compliance and persistence: A matter of choice? 2011;22:21-26.","DOI":"10.1007\/s00198-010-1274-6"},{"key":"10.1016\/j.clinthera.2015.03.023_bib12","series-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","year":"2005"},{"key":"10.1016\/j.clinthera.2015.03.023_bib13","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonate agents for osteoporosis-where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.023_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/GRF.0b013e3182a98295","article-title":"Controversies in osteoporosis management: concerns about bisphosphonate agents and when are \u201cdrug holidays\u201d required?","volume":"56","author":"McClung","year":"2013","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2015.03.023_bib15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MED.0b013e328317ca83","article-title":"Osteoporosis: how long should we treat?","volume":"15","author":"Sebba","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clinthera.2015.03.023_bib16","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.03.023_bib17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2015.03.023_bib18","first-page":"1807","article-title":"Proactive pharmaceutical care interventions decrease patients\u2019 nonadherence to osteoporosis medication","volume":"25","author":"Stuurman-Bieze","year":"2014","journal-title":"Osteoporos Intl"},{"key":"10.1016\/j.clinthera.2015.03.023_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2015.03.023_bib20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonate agents in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.03.023_bib21","first-page":"33","article-title":"Enabling medication therapy management","author":"Figge","year":"2008","journal-title":"US Pharmacist"},{"key":"10.1016\/j.clinthera.2015.03.023_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4140\/TCP.n.2013.39","article-title":"Use of bisphosphonate agents in older adults: how long is long enough?","volume":"28","author":"Dunn","year":"2013","journal-title":"Consult Pharm"},{"key":"10.1016\/j.clinthera.2015.03.023_bib23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.03.023_bib24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.03.023_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2015.03.023_bib26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.023_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 years versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2015.03.023_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2015.03.023_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2015.03.023_bib30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.023_bib31","doi-asserted-by":"crossref","unstructured":"Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 93:2149\u20132157","DOI":"10.1210\/jc.2007-2814"},{"key":"10.1016\/j.clinthera.2015.03.023_bib32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.03.023_bib33","first-page":"394","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"92","author":"Miller","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.03.023_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.clinthera.2015.03.023_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2015.03.023_bib36","first-page":"799","article-title":"Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling","volume":"12","author":"Lewiecki","year":"2009","journal-title":"IDrugs"},{"key":"10.1016\/j.clinthera.2015.03.023_bib37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-k inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2015.03.023_bib38","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2015.03.023_bib39","unstructured":"How long should you take certain osteoporosis drugs? FDA Consumer Health Information. May 2014. Retrieved from http:\/\/www.fda.gov\/ForConsumers\/ConsumerUpdates\/ucm309688.htm. Accessed September, 2014"},{"key":"10.1016\/j.clinthera.2015.03.023_bib40","article-title":"Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases","author":"Kanis","year":"2007","journal-title":"University of Sheffield, UK"},{"key":"10.1016\/j.clinthera.2015.03.023_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11914-012-0129-9","article-title":"Bisphosphonate drug holiday: choosing appropriate candidates","volume":"11","author":"Ro","year":"2013","journal-title":"Curr Osteoporos Rep"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815001654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815001654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T16:23:25Z","timestamp":1717863805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815001654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0149291815001654"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}